Hong Kong’s pharma outsourcing stocks shined on Friday. Joinn up over 10%; Wuxi Apptec up 9%; Pharmaron up 8%; Wuxi Bio up 4%.

WUXI APPTEC's 1H25 net profit attributable to shareholders was expected to be RMB8.561 billion, up 101.9% YoY. The revenue was expected to be approximately RMB20.799 billion, up 20.6%, with revenue from continuing operations growing by approximately 24.2%.